BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Teriflunomide: Phase III data

Top-line data from the double-blind, international Phase III TEMSO trial in 1,088 patients showed that once-daily 7 and 14 mg oral teriflunomide each met the primary endpoint of significantly reducing ARR from baseline to 2 years vs. placebo. The...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >